Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
CNM-Au8
product3 mentionslast seen Oct 20, 2026
Investigational first-in-class therapy targeting mitochondrial function and the NAD pathway for treatment of neurodegenerative diseases.
Relationships 7
- CNM-Au8applies toamyotrophic lateral sclerosis treatment99% confidence3 sources
- Clene Inc.developsCNM-Au899% confidence2 sources
- CNM-Au8applies tomultiple sclerosis treatment88% confidence1 source
- CNM-Au8applies toParkinson's disease treatment88% confidence1 source
- CNM-Au8depends onmitochondrial function targeting85% confidence1 source
- Clene Nanomedicine, Inc.developsCNM-Au885% confidence1 source
- U.S. Food and Drug AdministrationapprovesCNM-Au875% confidence1 source
Relationship
CNM-Au8applies toamyotrophic lateral sclerosis treatment
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGAROct 19, 2026Clene Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 9.01: Financial Statements and Exhibits
CNM-Au8 ® treatment of amyotrophic lateral sclerosis
- filingSEC EDGAROct 19, 2026Clene Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
seeking accelerated approval of CNM-Au8® for the treatment of amyotrophic lateral sclerosis (ALS)
- filingSEC EDGARSep 16, 2026Clene Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress